Guidance on the way pharma companies communicate about prescription medicines has been updated in the UK to cover use of social media channels for the first time.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh